Novo Nordisk A/S (NVO) 44.88 $NVO
Pharmaceuticals Manufacturers (Global) - Industry Report 2016: Individual Analysis of the Top 90 Companies Including Pfizer Inc, Novo Nordisk A/S & Allergan Inc - Research and Markets
BusinessWire - Fri Sep 23, 1:09PM CDT
Research and Markets has announced the addition of the "Pharmaceuticals Manufacturers (Global) - Industry Report" report to their offering.
AGN: 243.94 (+0.51), NVO: 44.88 (-0.69), PFE: 34.26 (+0.11)
Novo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba(R) label
Globe Newswire - Fri Sep 23, 7:27AM CDT
Bagsvaerd, Denmark, 23 September 2016 - Novo Nordisk today announced the submission of a supplemental application to the US Food and Drug Administration (FDA) for including data from the two SWITCH phase 3b trials in the label for Tresiba(R).
NVO: 44.88 (-0.69)
Watch for Novo Nordisk to Potentially Rebound After Falling 1.51% Yesterday
Comtex SmarTrend(R) - Wed Sep 21, 2:13PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $45.50 to a high of $46.03. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $45.63 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 44.88 (-0.69)
Analyzing the Global Diabetes Market 2016 - Leading Players are Takeda, Sanofi, Novo Nordisk, Merck & Co. & Eli Lilly & Co - Research and Markets
BusinessWire - Tue Sep 20, 3:17AM CDT
Research and Markets has announced the addition of the "Analyzing the Global Diabetes Market 2016" report to their offering.
NVO: 44.88 (-0.69), MRK: 62.96 (-0.06), LLY: 81.16 (-0.13)
Great Place to Work® and Fortune name Novo Nordisk as one of the country's best workplaces for women
PR Newswire - Thu Sep 15, 11:37AM CDT
Novo Nordisk is one of the 2016 Best Workplaces for Women, according to global research and consulting firm Great Place to Work® and Fortune.
NVO: 44.88 (-0.69)
Novo Nordisk (NVO) Presents Data on Obesity Drug Saxenda
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 8:54AM CDT
Novo Nordisk A/S (NVO) announced data from a post hoc analysis of the three-year part of the phase IIIa SCALE (Satiety and Clinical Adiposity ??? Liraglutide Evidence) Obesity and Prediabetes study on Saxenda.
JNJ: 118.81 (-0.65), NVO: 44.88 (-0.69), CBM: 46.60 (+0.30), ANIP: 66.64 (-0.17)
Drug Makers Stocks Technical Reports -- Pernix Therapeutics, Synergy Pharma, Novo Nordisk, and Apricus Biosciences
PR Newswire - Thu Sep 15, 6:40AM CDT
The global Drug Manufacturers space has seen moderate growth over the last five years due to increased demand for medicines, especially from emerging economies. This morning, Stock-Callers.com has issued research reports on four equities, namely, Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), and Apricus Biosciences Inc. (NASDAQ: APRI). Download the free research reports on these stocks today:
SGYP: 5.61 (+0.03), NVO: 44.88 (-0.69), PTX: 0.65 (+0.03), APRI: 0.35 (-0.05)
Upgrade Alert for Novo Nordisk (NVO)
Comtex SmarTrend(R) - Wed Sep 14, 3:54AM CDT
Novo Nordisk (NYSE:NVO) was upgraded from Neutral to Outperform at Exane BNP Paribas today. The stock closed yesterday at $45.84 on volume of 4.7 million shares, above average daily volume of 1.0 million. Novo Nordisk A/S develops, produces, and markets pharmaceutical products. The Company focuses on diabetes care and offers insulin delivery systems and other diabetes products. Novo Nordisk also works in areas such as haemostatis management, growth disorders, and hormone replacement therapy. The Company offers educational and training materials. Novo Nordisk markets worldwide.
NVO: 44.88 (-0.69)
Pharma Stock Roundup: Drug Pricing Remains in Focus, Merck Drops Odanacatib
Arpita Dutt - Zacks Investment Research - Fri Sep 09, 7:14AM CDT
The drug pricing controversy and Mylan (MYL) remained in the news this week as well.
AGN: 243.94 (+0.51), NVO: 44.88 (-0.69), MRK: 62.96 (-0.06), MYL: 42.06 (-0.53), LLY: 81.16 (-0.13), BMY: 56.48 (+0.06), SNY: 38.35 (-0.22)
Novo Nordisk Inc. issues voluntary nationwide recall of six batches of GlucaGen® HypoKit® (glucagon [rDNA origin] for injection) due to detached needles on the syringe in the kit
PR Newswire - Thu Sep 08, 1:16PM CDT
Novo Nordisk Inc. is recalling six batches of the GlucaGen® HypoKit® in the U.S. due to two customer complaints from the UK and Portugal involving detached needles on the syringe with Sterile Water for Injection (SWFI). GlucaGen® HypoKit® is indicated for the treatment of severe hypoglycemia (low blood sugar) in patients with diabetes who are treated with insulin. A syringe with a detached needle cannot be used as prescribed.
NVO: 44.88 (-0.69)
Novo Nordisk's IDegLira Review Period Extended in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Sep 05, 7:31AM CDT
Novo Nordisk (NVO) announced that the FDA has extended the review period of a NDA for IDegLira for the treatment of adults with type II diabetes by three months.
NVO: 44.88 (-0.69), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07), PCRX: 36.86 (-0.66)
FDA extends regulatory review period for IDegLira by three months
Globe Newswire - Fri Sep 02, 4:47PM CDT
Bagsvaerd, Denmark, 2 September 2016 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has extended the regulatory review period for IDegLira, the fixed-ratio combination of insulin degludec and liraglutide in adults with type 2 diabetes.
NVO: 44.88 (-0.69)
SmarTrend Watching for Potential Rebound in Shares of Novo Nordisk After 1.36% Loss
Comtex SmarTrend(R) - Fri Sep 02, 12:47PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $45.36 to a high of $45.84. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $46.13 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 44.88 (-0.69)
Downgrade Alert for Novo Nordisk (NVO)
Comtex SmarTrend(R) - Fri Sep 02, 3:13AM CDT
Novo Nordisk (NYSE:NVO) was downgraded from Overweight to Equal Weight at Morgan Stanley today. The stock closed yesterday at $46.34 on volume of 2.8 million shares, above average daily volume of 1.0 million. Potential upside of 53.4% exists for Novo Nordisk, based on a current level of $46.34 and analysts' average consensus price target of $71.10. The stock should run into initial resistance at its 200-day moving average (MA) of $55.18 and subsequent resistance at its 50-day MA of $55.23.
NVO: 44.88 (-0.69)
Lars Rebien Sorensen to retire as CEO of Novo Nordisk; Lars Fruergaard Jorgensen appointed as successor
Globe Newswire - Thu Sep 01, 1:06AM CDT
Bagsvaerd, Denmark, 1 September 2016 - Novo Nordisk A/S today announced that Lars Rebien Sorensen, president and chief executive officer, will retire from the company by the end of 2016. Lars Fruergaard Jorgensen, currently executive vice president and head of Corporate Development, will succeed him, effective 1 January 2017. The company also announced a number of other executive-level changes, effective immediately.
NVO: 44.88 (-0.69)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 44.88 (-0.69), MRK: 62.96 (-0.06), AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13), GSK: 43.42 (-0.16)
Look for Shares of Novo Nordisk to Potentially Pullback after Yesterday's 1.39% Rise
Comtex SmarTrend(R) - Mon Aug 22, 12:54PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $47.39 to a high of $47.98. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $47.29 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVO: 44.88 (-0.69)
Hip-Hop Legend Rev Run and Wife Justine Simmons Unveil Experiential Photo Exhibit with Novo Nordisk Depicting the Millions of Americans at Risk of Diabetes
PR Newswire - Mon Aug 15, 7:30AM CDT
Novo Nordisk today unveiled the "Am I at Risk?" traveling exhibit as an extension of its Ask.Screen.Know.® program urging adults to know their risk of type 2 diabetes at 30th Street Station in Philadelphia. Twenty-nine million Americans are living with diabetes and 1 in 4 do not know it.1 The exhibit illustrates the many different faces of Americans who are at risk of diabetes, including Ask.Screen.Know.® ambassadors Rev Run and Justine Simmons.
NVO: 44.88 (-0.69)
Pharmaceuticals Manufacturers (Global) - Industry Report 2016: Individual Analysis of the Top 90 Companies Including Pfizer Inc, Novo Nordisk A/S & Allergan Inc - Research and Markets
BusinessWire - Fri Sep 23, 1:09PM CDT
Research and Markets has announced the addition of the "Pharmaceuticals Manufacturers (Global) - Industry Report" report to their offering.
AGN: 243.94 (+0.51), NVO: 44.88 (-0.69), PFE: 34.26 (+0.11)
Novo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba(R) label
Globe Newswire - Fri Sep 23, 7:27AM CDT
Bagsvaerd, Denmark, 23 September 2016 - Novo Nordisk today announced the submission of a supplemental application to the US Food and Drug Administration (FDA) for including data from the two SWITCH phase 3b trials in the label for Tresiba(R).
NVO: 44.88 (-0.69)
Watch for Novo Nordisk to Potentially Rebound After Falling 1.51% Yesterday
Comtex SmarTrend(R) - Wed Sep 21, 2:13PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $45.50 to a high of $46.03. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $45.63 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 44.88 (-0.69)
Analyzing the Global Diabetes Market 2016 - Leading Players are Takeda, Sanofi, Novo Nordisk, Merck & Co. & Eli Lilly & Co - Research and Markets
BusinessWire - Tue Sep 20, 3:17AM CDT
Research and Markets has announced the addition of the "Analyzing the Global Diabetes Market 2016" report to their offering.
NVO: 44.88 (-0.69), MRK: 62.96 (-0.06), LLY: 81.16 (-0.13)
Great Place to Work® and Fortune name Novo Nordisk as one of the country's best workplaces for women
PR Newswire - Thu Sep 15, 11:37AM CDT
Novo Nordisk is one of the 2016 Best Workplaces for Women, according to global research and consulting firm Great Place to Work® and Fortune.
NVO: 44.88 (-0.69)
Novo Nordisk (NVO) Presents Data on Obesity Drug Saxenda
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 8:54AM CDT
Novo Nordisk A/S (NVO) announced data from a post hoc analysis of the three-year part of the phase IIIa SCALE (Satiety and Clinical Adiposity ??? Liraglutide Evidence) Obesity and Prediabetes study on Saxenda.
JNJ: 118.81 (-0.65), NVO: 44.88 (-0.69), CBM: 46.60 (+0.30), ANIP: 66.64 (-0.17)
Drug Makers Stocks Technical Reports -- Pernix Therapeutics, Synergy Pharma, Novo Nordisk, and Apricus Biosciences
PR Newswire - Thu Sep 15, 6:40AM CDT
The global Drug Manufacturers space has seen moderate growth over the last five years due to increased demand for medicines, especially from emerging economies. This morning, Stock-Callers.com has issued research reports on four equities, namely, Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), and Apricus Biosciences Inc. (NASDAQ: APRI). Download the free research reports on these stocks today:
SGYP: 5.61 (+0.03), NVO: 44.88 (-0.69), PTX: 0.65 (+0.03), APRI: 0.35 (-0.05)
Upgrade Alert for Novo Nordisk (NVO)
Comtex SmarTrend(R) - Wed Sep 14, 3:54AM CDT
Novo Nordisk (NYSE:NVO) was upgraded from Neutral to Outperform at Exane BNP Paribas today. The stock closed yesterday at $45.84 on volume of 4.7 million shares, above average daily volume of 1.0 million. Novo Nordisk A/S develops, produces, and markets pharmaceutical products. The Company focuses on diabetes care and offers insulin delivery systems and other diabetes products. Novo Nordisk also works in areas such as haemostatis management, growth disorders, and hormone replacement therapy. The Company offers educational and training materials. Novo Nordisk markets worldwide.
NVO: 44.88 (-0.69)
Pharma Stock Roundup: Drug Pricing Remains in Focus, Merck Drops Odanacatib
Arpita Dutt - Zacks Investment Research - Fri Sep 09, 7:14AM CDT
The drug pricing controversy and Mylan (MYL) remained in the news this week as well.
AGN: 243.94 (+0.51), NVO: 44.88 (-0.69), MRK: 62.96 (-0.06), MYL: 42.06 (-0.53), LLY: 81.16 (-0.13), BMY: 56.48 (+0.06), SNY: 38.35 (-0.22)
Novo Nordisk Inc. issues voluntary nationwide recall of six batches of GlucaGen® HypoKit® (glucagon [rDNA origin] for injection) due to detached needles on the syringe in the kit
PR Newswire - Thu Sep 08, 1:16PM CDT
Novo Nordisk Inc. is recalling six batches of the GlucaGen® HypoKit® in the U.S. due to two customer complaints from the UK and Portugal involving detached needles on the syringe with Sterile Water for Injection (SWFI). GlucaGen® HypoKit® is indicated for the treatment of severe hypoglycemia (low blood sugar) in patients with diabetes who are treated with insulin. A syringe with a detached needle cannot be used as prescribed.
NVO: 44.88 (-0.69)
Novo Nordisk's IDegLira Review Period Extended in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Sep 05, 7:31AM CDT
Novo Nordisk (NVO) announced that the FDA has extended the review period of a NDA for IDegLira for the treatment of adults with type II diabetes by three months.
NVO: 44.88 (-0.69), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07), PCRX: 36.86 (-0.66)
FDA extends regulatory review period for IDegLira by three months
Globe Newswire - Fri Sep 02, 4:47PM CDT
Bagsvaerd, Denmark, 2 September 2016 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has extended the regulatory review period for IDegLira, the fixed-ratio combination of insulin degludec and liraglutide in adults with type 2 diabetes.
NVO: 44.88 (-0.69)
SmarTrend Watching for Potential Rebound in Shares of Novo Nordisk After 1.36% Loss
Comtex SmarTrend(R) - Fri Sep 02, 12:47PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $45.36 to a high of $45.84. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $46.13 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NVO: 44.88 (-0.69)
Downgrade Alert for Novo Nordisk (NVO)
Comtex SmarTrend(R) - Fri Sep 02, 3:13AM CDT
Novo Nordisk (NYSE:NVO) was downgraded from Overweight to Equal Weight at Morgan Stanley today. The stock closed yesterday at $46.34 on volume of 2.8 million shares, above average daily volume of 1.0 million. Potential upside of 53.4% exists for Novo Nordisk, based on a current level of $46.34 and analysts' average consensus price target of $71.10. The stock should run into initial resistance at its 200-day moving average (MA) of $55.18 and subsequent resistance at its 50-day MA of $55.23.
NVO: 44.88 (-0.69)
Lars Rebien Sorensen to retire as CEO of Novo Nordisk; Lars Fruergaard Jorgensen appointed as successor
Globe Newswire - Thu Sep 01, 1:06AM CDT
Bagsvaerd, Denmark, 1 September 2016 - Novo Nordisk A/S today announced that Lars Rebien Sorensen, president and chief executive officer, will retire from the company by the end of 2016. Lars Fruergaard Jorgensen, currently executive vice president and head of Corporate Development, will succeed him, effective 1 January 2017. The company also announced a number of other executive-level changes, effective immediately.
NVO: 44.88 (-0.69)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 44.88 (-0.69), MRK: 62.96 (-0.06), AMGN: 174.80 (-0.82), LLY: 81.16 (-0.13), GSK: 43.42 (-0.16)
Look for Shares of Novo Nordisk to Potentially Pullback after Yesterday's 1.39% Rise
Comtex SmarTrend(R) - Mon Aug 22, 12:54PM CDT
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $47.39 to a high of $47.98. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $47.29 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVO: 44.88 (-0.69)
Hip-Hop Legend Rev Run and Wife Justine Simmons Unveil Experiential Photo Exhibit with Novo Nordisk Depicting the Millions of Americans at Risk of Diabetes
PR Newswire - Mon Aug 15, 7:30AM CDT
Novo Nordisk today unveiled the "Am I at Risk?" traveling exhibit as an extension of its Ask.Screen.Know.® program urging adults to know their risk of type 2 diabetes at 30th Street Station in Philadelphia. Twenty-nine million Americans are living with diabetes and 1 in 4 do not know it.1 The exhibit illustrates the many different faces of Americans who are at risk of diabetes, including Ask.Screen.Know.® ambassadors Rev Run and Justine Simmons.
NVO: 44.88 (-0.69)
